Prizes Recognizing Innovation in ALS

The BrainGate team is developing groundbreaking Brain Computer Interfaces (BCIs) to restore communication, mobility and independence in a variety of neurological diseases including ALS, spinal cord injury, stroke. Learn more.

The team responsible for the establishment of neurofilament biomarkers as an early diagnostic and prognostic biomarker for ALS. Learn more.

The team that brought innovation, rapid development, and efficacy in Phase 2 clinical trials that led to the FDA approval of Relyvrio as a new treatment for ALS, The FDA approved Relyvrio in September, after clinical data showed that the medication slowed disease progression, extending the lives of patients by several months. Learn more.

PRO-ACT, the Pooled Resource Open-Access ALS Clinical Trials Database, for building the largest ALS clinical trials dataset ever created. PRO-ACT merges data from existing publicly- and privately-conducted ALS clinical trials to generate an invaluable resource for accelerating discovery in the field of ALS. Learn more.

Project MinE, for developing the largest single disease whole genome sequencing project in the world. Award recipients include Professor Ammar Al-Chalabi of Kings College London, Professor Jan H. Veldink of University Medical Center Utrecht, Professor Orla Hardiman of Trinity College Dublin, Professor Phillip Van Damme of University of Leuven, Belgium, Professor Leonard H. van den Berg of University Medical Center Utrecht, Professor Jonathan D. Glass of Emory University, Professor John Landers of University of Massachusetts Medical School and Ms. Evy Reviers of EUpALS, Belgium. Learn more.

Timothy Miller, MD, PhD, of Washington University School of Medicine in St. Louis; Don Cleveland, PhD, of the Ludwig Institute at the University of California at San Diego; Richard Smith, MD, of the Center of Neurological Study in La Jolla, California; Toby Ferguson, MD, PhD, for Biogen and Frank Bennett, PhD, for Ionis Pharmaceuticals; for their work creating the first clinical trial of antisense oligonucleotide (ASO) therapy for ALS. Learn more.

Team Gleason, for providing exceptional care for those living with ALS and providing those with ALS access to cutting-edge technology. Learn more.

The teams from both ALS ONE and Compassionate Care ALS (CCALS). Learn more.

The team from ALSUntangled, created by Richard Bedlack, M.D, PhD, Professor of Neurology at Duke University and Director of the Duke ALS clinic, for their work in facilitating more informed decisions treatments for ALS. Learn more.

Penn State Health Milton S. Hershey Medical Center ALS Clinic, for pioneering decentralized multidisciplinary ALS care using digital health and targeted remote monitoring technologies. Learn more.

Dr. Richard Robitaille for his work focused on understanding the mechanisms underlying neuromuscular junction (NMJ) impairments in ALS, resulting in a clinical trial. Learn more.

The team responsible for the development of a therapy to target FUS in people living with ALS demonstrating slowing and even reversing the disease course of FUS ALS in some people. Learn more.

The Answer ALS Team and the team responsible for identifying Stathmin-2 as a therapeutic target for ALS. Learn more

Marc Freeman, PhD and Michael Coleman, PhD, for their excellence in transformative scientific discoveries focused on repair of neurological function in ALS. Learn more.

Anushka Sanyal, a Senior at Stanford University in California, for her project on A Novel RNA-based Chaperone that Protects Against TDP-43 Toxicity in ALS. Learn more.

Deland Liu, PhD student, for his project integrating artificial intelligence (AI) modules in brain-computer interfaces to restore efficient communication for ALS patients. Learn more.